The US Food an Drug Administration has approved a new indication for Jemperli (dostarlimab-gxly), a programmed cell death receptor-1 (PD-1) blocking antibody from UK pharma major GlaxoSmithKline (LSE: GSK).
Jemperli was approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
This milestone builds on the approvals GSK received in April for Jemperli in endometrial cancer in both the USA and the EU earlier this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze